 |
|
|
| |
Point-of-Care 60-minute Rapid HCV RNA Screening
for IDUs Studies at AASLD & FDA Approval
|
| |
| |
A big key NOW to HCV elimination in the USA is approval for rapid 60-minute finger-stick HCV RNA point-of-care test, which is used in Europe & Australia, here are some studies from AASLD last week on these. And of course the federal government & Congress have not been convinced to provide more than $39 mill to the CDC for hepatitis. We need $400 mill year for 6 years to eliminate HCV, the CDC says. PLUS at AASLD all the trends are going in the wrong direction: increased HCC rates, treatment rates are down & not adequate to get to elimination, and screening rates are no where near that needed - all because we do not have a fully funded federal HCV Elimination Program.
Rapid HCV Screening for IDUs Studies at AASLD - Several studies & the new FDA Order which Will facilitate the new finger stick RNA 60-minutes tests to be FDA Approved
AASLD: Rapid Hepatitis C Treatment Initiation in Young People Who Inject Drugs: Final Results from the HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial - (11/15/21) in NYC
AASLD: HEPATITIS C TREATMENT IN THE UNITED STATES, 2014-2020 numbers of treated is "below that needed to ensure elimination in USA by 2030, increased screening needed, remove all rstrictions" - (11/17/21)
AASLD: A COMMUNITY-BASED TRIAL OF HEPATITIS C TREATMENT AT POINT OF DIAGNOSIS FOR MARGINALIZED POPULATIONS: PRELIMINARY RESULTS FROM THE NO ONE WAITS (NOW) STUDY - (11/16/21)
Point-of-care HCV RNA testing with peer-led and nurse-based support to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study - see study results below - (11/22/21)
FDA In Brief: FDA Issues Final Orders Reclassifying Certain Hepatitis C Diagnostic Tests from Class III to Class II - improving submission process for HCV point-of-care HCV RNA testing - (11/22/21)
AASLD: HCV-RNA VIRAL LOAD FINGERSTICK ASSAY AS A SIMPLIFIED STRATEGY FOR SCREENING AND LINKAGE TO CARE OF PEOPLE WHO USE DRUGS ATTENDING ITALIAN ADDICTION TREATMENT CENTRES: A PILOT PROJECT - (11/15/21)
AASLD:IMPLEMENTATION OF RAPID POINT-OF-CARE DIAGNOSTIC SYSTEMS TO SUPPORT HCV MICRO-ELIMINATION STRATEGIES IN A TERTIARY HOSPITAL IN SPAIN (12/01/21)
AASLD: POINT-OF-CARE TESTING FOR HEPATITIS C IN PUBLIC CLINICAL LABORATORIES REVEALS SIGNIFICANT RATES OF HIDDEN HCV AMONG ELDERLY POPULATION IN SOUTHERN ITALY (12/01/21)
AASLD: POTENTIAL COST-EFFECTIVENESS OF A MACHINE LEARNING ALGORITHM TO IDENTIFY UNDIAGNOSED HEPATITIS C PATIENTS IN THE UNITED STATES (11/30/21)
AASLD: PROVISION OF HEPATITIS C CARE IN A FEDERALLY QUALIFIED HEALTH CENTER DURING THE COVID-19 PANDEMIC AND BEYOND - telemedicine & delivery of DAA medications (11/30/21)
AASLD: USE OF SOFOSBUVIR/VELPATASVIR IN TEST AND TREAT STRATEGY IN FRANCE: SNAPSHOT ANALYSIS OF PROSPECTIVE COHORT STUDY HELIOS 3 - (11/12/21)
AASLD: HCV TREATMENT AMONG ACTIVE INNER CITY DRUG USERS WITH GLECAPREVIR/PIBRENTASVIR: THE GRAND PLAN STUDY (11/30/21)
AASLD: HCV CASCADE OF CARE [Big Gaps] AND NEXT STEPS FOR HCV ELIMINATION IN THE UNITED STATES FOLLOWING THE COVID-19 PANDEMIC - new updated improved HCV screening guidelines needed including for pregnant women & high-risk populations (11/22/21)
Early HCV Treatment During Acute HCV Within few, 6 Months of Infection with Short-Duration of 4-6 Weeks - (12/09/21)
AASLD: CONCURRENT FATTY LIVER IS ASSOCIATED WITH HIGHER RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS (12/03/21)
AASLD: GLOBAL TRENDS IN CAUSE-SPECIFIC MORTALITY AND DISABILITY ADJUSTED LIFE YEARS RELATED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS FROM 2010 TO 2019 (11/22/21)
100 reports
AASLD
The Liver Meeting
November Fri, Nov 12
- Mon, Nov 15, 2021
HBV at AASLD
HCV at AASLD
Fatty Liver & NASH at AASLD
|
| |
|
|
|
|
|
